Teladoc Health (NYSE:TDOC – Free Report) had its price objective increased by Deutsche Bank Aktiengesellschaft from $10.00 to $12.00 in a research note released on Friday morning, Benzinga reports. They currently have a hold rating on the health services provider’s stock.
TDOC has been the subject of several other reports. Royal Bank of Canada lifted their price objective on Teladoc Health from $9.00 to $10.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. DA Davidson reduced their price objective on Teladoc Health from $12.00 to $8.00 and set a “neutral” rating on the stock in a research report on Thursday, August 1st. Stifel Nicolaus decreased their price objective on Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, August 1st. TD Cowen cut their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Thursday, October 31st. Finally, Barclays raised their price target on shares of Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Fourteen research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $11.97.
Get Our Latest Stock Analysis on Teladoc Health
Teladoc Health Stock Down 3.7 %
Teladoc Health (NYSE:TDOC – Get Free Report) last posted its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.10. The firm had revenue of $640.51 million during the quarter, compared to the consensus estimate of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. On average, equities research analysts forecast that Teladoc Health will post -1.19 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Mala Murthy sold 8,750 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $62,650.00. Following the sale, the chief financial officer now directly owns 85,767 shares in the company, valued at approximately $614,091.72. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Teladoc Health news, Director Thomas Mckinley purchased 4,000 shares of Teladoc Health stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of $7.69 per share, with a total value of $30,760.00. Following the completion of the acquisition, the director now owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mala Murthy sold 8,750 shares of Teladoc Health stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total value of $62,650.00. Following the sale, the chief financial officer now owns 85,767 shares in the company, valued at $614,091.72. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,051 shares of company stock worth $257,565 over the last quarter. 0.95% of the stock is owned by corporate insiders.
Institutional Trading of Teladoc Health
A number of hedge funds have recently made changes to their positions in TDOC. Clearline Capital LP raised its stake in Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after buying an additional 3,483,665 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Teladoc Health by 195.3% in the second quarter. The Manufacturers Life Insurance Company now owns 95,307 shares of the health services provider’s stock worth $932,000 after purchasing an additional 63,028 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Teladoc Health by 74.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 20,568 shares of the health services provider’s stock valued at $311,000 after purchasing an additional 8,750 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of Teladoc Health by 170.7% during the second quarter. Mackenzie Financial Corp now owns 107,255 shares of the health services provider’s stock worth $1,049,000 after purchasing an additional 67,640 shares during the period. Finally, Janney Montgomery Scott LLC lifted its position in shares of Teladoc Health by 188.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 31,594 shares of the health services provider’s stock worth $477,000 after buying an additional 20,651 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.
About Teladoc Health
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Recommended Stories
- Five stocks we like better than Teladoc Health
- Trading Halts Explained
- Intel: Is Now the Time to Be Brave?
- 3 Warren Buffett Stocks to Buy Now
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Ride Out The Recession With These Dividend Kings
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.